InChI
1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
SMILES string
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
InChI key
KUVIULQEHSCUHY-XYWKZLDCSA-N
grade
pharmaceutical primary standard
API family
beclometasone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Beclomethasone dipropionate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Beclomethasone Dipropionate Compounded Oral Solution
- Betamethasone Dipropionate
- Betamethasone Dipropionate Cream
- Betamethasone Dipropionate Lotion
- Betamethasone Dipropionate Ointment
- Betamethasone Valerate
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2 - STOT RE 2
target_organs
Adrenal gland,Immune system,Bone
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
A R Boobis
Respiratory medicine, 92 Suppl B, 2-6 (1999-04-08)
The physicochemical and pharmacokinetic characteristics of BDP and budesonide are somewhat different, but the overall result is that both are well suited for use as inhaled corticosteroids. Both BDP and budesonide are metabolized primarily by the liver, with one of
P Chervinsky
Clinical therapeutics, 18(5), 790-796 (1996-09-01)
A new double-strength (84 micrograms/spray) formulation of beclomethasone dipropionate (BDP-ds) as an aqueous suspension has been introduced to control symptoms of allergic rhinitis with once-daily intranasal dosing. This paper reviews the results of three clinical reports which show that BDP-ds
R N Brogden et al.
Drugs, 28(2), 99-126 (1984-08-01)
Inhaled beclomethasone dipropionate is now well established in the management of asthma. Studies conducted over the last decade, and since the drug was previously reviewed in the Journal, have confirmed that inhaled beclomethasone dipropionate 400 to 800 micrograms daily can
B Davies
The British journal of clinical practice, 47(2), 87-93 (1993-03-01)
Several reports have claimed that beclomethasone dipropionate (BDP) and budesonide (BUD) differ with regard to therapeutic efficacy and associated adverse effects, based either upon clinical data, or upon theoretical considerations. Although long-term comparisons are lacking, the consensus of numerous studies
S E Libretto
Archives of toxicology, 69(8), 509-525 (1995-01-01)
This paper reviews the published toxicity of beclomethasone dipropionate (BDP). BDP is a synthetic glucocorticosteroid which has a powerful local anti-inflammatory effect but little systemic action. It has been developed for both dermatological and inhaled applications. LD50 values and other
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持